Mrs Kathleen Larson, PA-C | |
437 3rd Ave Se, Garrison, ND 58540-7235 | |
(701) 463-2245 | |
(701) 463-6543 |
Full Name | Mrs Kathleen Larson |
---|---|
Gender | Female |
Speciality | Physician Assistant - Medical |
Location | 437 3rd Ave Se, Garrison, North Dakota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912987843 | NPI | - | NPPES |
13123 | Other | ND | BLUE CROSS/BLUE SHIELD |
13077 | Medicaid | ND |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363AM0700X | Physician Assistant - Medical | PAC0139 (North Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Kathleen Larson, PA-C Po Box 9, Garrison, ND 58540-0009 Ph: (701) 463-2245 | Mrs Kathleen Larson, PA-C 437 3rd Ave Se, Garrison, ND 58540-7235 Ph: (701) 463-2245 |
News Archive
Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.
BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.
BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.
Among men undergoing biopsy for suspected prostate cancer, targeted magnetic resonance/ultrasound fusion biopsy, compared with a standard biopsy technique, was associated with increased detection of high-risk prostate cancer and decreased detection of low-risk prostate cancer, according to a study in the January 27 issue of JAMA.
› Verified 2 days ago
Arthur J Renner, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 437 3rd Ave Se, Garrison, ND 58540 Phone: 701-463-2245 Fax: 701-463-6543 | |
Luanna Graeber, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 437 3rd Ave Se, Garrison, ND 58540 Phone: 701-463-2245 Fax: 701-463-6543 |